Study ID

209762/147

Clinical Study ID

209762/147 (MeMuRu-147)

Study Title Phase IV open study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ live attenuated Measles-Mumps-Rubella (MMR) vaccine when given to healthy children at the age of 12 to 18 months in Singapore.
Patient Level Data Study Listed on ClinicalStudyDataRequest.com
Clinicaltrials.gov Identifier NCT00388440
Sponsor GlaxoSmithKline
Collaborators N/A
Phase phase 4
Study Recruitment Status Completed
Generic Name Measles, Mumps, Rubella Vaccine
Trade Name Priorix
Study Indication Measles; Mumps; Rubella

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.